|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240.50 USD | -2.03% |
|
+0.77% | +12.78% |
| 05-07 | Ascendis Pharma A/S, Q1 2026 Earnings Call, May 07, 2026 | |
| 05-07 | Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Capitalization | 12.85B 14.94B 11.75B 11.21B 20.56B 1,433B 20.9B 141B 54.56B 680B 56.06B 54.86B 2,370B | P/E ratio 2026 * |
15.3x | P/E ratio 2027 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise value | 11.96B 13.9B 10.93B 10.43B 19.12B 1,333B 19.44B 131B 50.76B 633B 52.15B 51.03B 2,205B | EV / Sales 2026 * |
8.87x | EV / Sales 2027 * | 5.78x |
| Free-Float |
96.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ascendis Pharma A/S
| 1 day | -2.03% | ||
| 1 week | +0.77% | ||
| Current month | +4.85% |
| 1 week | 234.38 |  | 248 |
| 1 month | 216.22 | | 250.27 |
| Current year | 216.22 | | 250.27 |
| 1 year | 216.22 | | 250.27 |
| 3 years | 216.22 | | 250.27 |
| 5 years | 216.22 | | 250.27 |
| 10 years | 216.22 | | 250.27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
CEO | Chief Executive Officer | 67 | 30/11/2007 |
Scott Smith
DFI | Director of Finance/CFO | 53 | 07/08/2016 |
Aimee Shu
CTO | Chief Tech/Sci/R&D Officer | 50 | 30/06/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Mikkelsen
BRD | Director/Board Member | 67 | 30/11/2007 |
Albert Cha
CHM | Chairman | 54 | 27/05/2021 |
Lisa Bright
BRD | Director/Board Member | 59 | 31/03/2017 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.03% | +0.77% | - | - | 14.94B | |
| -1.01% | -2.82% | -18.17% | -19.32% | 41.67B | |
| -3.73% | -6.04% | +28.41% | +22.76% | 32.6B | |
| -2.55% | +2.71% | +268.39% | +468.32% | 30.97B | |
| -0.91% | -5.37% | +18.41% | -11.55% | 28.23B | |
| -3.23% | -4.84% | +27.50% | +22.65% | 26.41B | |
| +6.21% | -2.39% | +176.35% | +4,385.95% | 14.13B | |
| -1.92% | -1.95% | +121.19% | +106.25% | 12.27B | |
| -0.20% | -0.10% | +5.63% | -1.89% | 12.12B | |
| -0.93% | -2.06% | +35.86% | +100.75% | 11.86B | |
| Average | -1.03% | -1.86% | +73.73% | +563.77% | 22.52B | |
| Weighted average by Cap. | -1.48% | -2.17% | +67.53% | +376.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.35B 1.57B 1.23B 1.18B 2.16B 150B 2.19B 14.79B 5.72B 71.35B 5.88B 5.75B 249B | 1.96B 2.28B 1.79B 1.71B 3.14B 219B 3.19B 21.53B 8.33B 104B 8.56B 8.38B 362B |
| Net income | 895M 1.04B 818M 780M 1.43B 99.74B 1.45B 9.81B 3.8B 47.35B 3.9B 3.82B 165B | 626M 728M 573M 546M 1B 69.82B 1.02B 6.87B 2.66B 33.15B 2.73B 2.67B 115B |
| Net Debt | -896M -1.04B -819M -782M -1.43B -99.93B -1.46B -9.83B -3.8B -47.44B -3.91B -3.83B -165B | -1.51B -1.76B -1.38B -1.32B -2.42B -169B -2.46B -16.6B -6.42B -80.07B -6.6B -6.46B -279B |
Employees
1,189
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/26 | 240.50 $ | -2.03% | 471,347 |
| 14/05/26 | 245.49 $ | +0.78% | 278,119 |
| 13/05/26 | 243.58 $ | +2.50% | 432,458 |
| 12/05/26 | 237.65 $ | -0.43% | 879,757 |
| 11/05/26 | 238.67 $ | +0.00% | 682,348 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
206.95EUR
Average target price
252.76EUR
Spread / Average Target
+22.14%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASND Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition